CARUSO JAMES V 4

What Happened
James V. Caruso, CEO of Cellectar Biosciences (CLRB), made two purchases on 2026-05-07. He bought 8,680 common shares in an open-market purchase at $2.88 per share for a total cash outlay of $24,998. The filing also shows acquisition of 26,040 shares labeled as a derivative at $0.01 per share ($260). Both transactions are reported as purchases (code P), which are typically seen as a direct insider buy and could be viewed as a bullish signal compared with sales.

Key Details

• Transaction dates: 2026-05-07 (both transactions)
• Prices and totals: 8,680 shares @ $2.88 = $24,998; 26,040 derivative shares @ $0.01 = $260
• Transaction codes: P (purchase) for both entries; second entry is identified as a "Derivative" in the filing
• Footnote: F1 notes expiration timing for tranches (Tranche A = 1 year; Tranche B = 2 years; Tranche C = 5 years from stockholder approval) — suggests the derivative relates to tranche-based instruments with different expirations
• Shares owned after transaction: not specified in the provided filing excerpt
• Filing timeliness: Form 4 was filed 2026-05-11 for trades on 2026-05-07 — this is later than the typical 2-business-day Form 4 deadline (the filing does not flag a late filing code here)

Context: The first purchase is a straightforward open-market buy. The second line is a low-cost derivative acquisition (likely issuance/conversion of a derivative instrument per the footnote), not an immediate sale; derivative entries can reflect warrants, options or tranche-based instruments. The filing is factual and does not state the insider’s motivation.